This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Innate Pharma S.A.
Drug Names(s): IPH-1101, IPH1101, Phosphostim, BrHPP
Description: IPH 1101 is an agonist of T-gamma-9-delta-2 lymphocytes, obtained through chemical synthesis. It is a structural analogue of bacterial phosphoantigens, identified as natural activators of T-gamma-9-delta-2 lymphocytes.
IPH 1101 potentiates the cytotoxic activity of T-gamma-9-delta-2 cells and triggers the synthesis of pro-inflammatory cytokines that in turn lead to the recruitment of other cell effectors (such as NK cells), thereby facilitating the introduction of antigens in the immune system and starting an adaptive immune response.
Innate Pharma develops IPH 1101 to be active through intravenous administration, in association with low doses of IL-2, enabling the expansion of the gamma-9-delta-2 T cell population.
IPH 1101 News
Additional information available to subscribers only: